FDA Implements Accelerated Review Programs and AI to Boost Drug Approval Efficiency
The FDA announced a new initiative to expedite drug reviews for medicines aligned with U.S. national priorities, aiming to review some drugs within one to two months through special vouchers and streamlined processes, reflecting a shift towards faster approvals especially for treatments addressing critical health issues.